文献速递前列腺癌男科与性医学

美国跨性别女性前列腺癌发病率:一项大型数据库分析

Incidence of prostate cancer in transgender women in the US: a large database analysis.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-02-07

该研究利用TriNetX大型数据库与SEER数据,比较跨性别女性与顺性别男性的前列腺癌风险。结果显示,跨性别女性总体前列腺癌风险较顺性别男性低2.56倍;在50-64岁接受激素治疗的跨性别女性中,风险降低2.06倍。作者认为跨性别女性前列腺癌可能并不像既往认为的那样罕见。

要点

  • 跨性别女性总体前列腺癌风险较顺性别男性低2.56倍。
  • 50-64岁接受激素治疗的跨性别女性风险降低2.06倍。
  • 作者认为跨性别女性前列腺癌可能并不像既往认为的那样罕见。

核心结论

  • 跨性别女性前列腺癌风险较顺性别男性低2.56倍,在50-64岁接受激素治疗者中风险降低2.06倍,作者认为该癌种可能并不像既往认为的那样罕见。

研究设计与样本

  • 基于TriNetX大型数据库与SEER数据的比较分析,比较跨性别女性与顺性别男性的前列腺癌风险。

主要发现

  • 跨性别女性总体前列腺癌风险较顺性别男性低2.56倍。
  • 50-64岁接受激素治疗的跨性别女性前列腺癌风险降低2.06倍。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The risk of prostate cancer among transgender women undergoing medical and surgical gender-affirming interventions remains unclear, though up to a fivefold decreased risk has been reported in comparison to cisgender men. In this study, we conducted a comparative analysis of the risk of prostate cancer among transgender women (TW) using data from TriNetX, a large database, versus SEER. Our findings indicate that, overall, transgender women exhibited a 2.56-fold lower risk of prostate cancer compared to cisgender men. Specifically, among TW on hormone therapy between ages 50-64, we observed a 2.06-fold decrease in risk. Contrary to the previous perception of prostate cancer being rare in transgender women, our study suggests that it may not be as uncommon as previously believed.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Loria M, Gilbert D, Tabernacki T, et al. Incidence of prostate cancer in transgender women in the US: a large database analysis. Prostate Cancer Prostatic Dis. 2024. PMID: 38326392. doi:10.1038/s41391-024-00804-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。